重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白对中重度银屑病患者的临床意义

Restructuring Ⅱ Type of Tumor Necrosis Factor Receptor-Antibody Fusion Protein in Patients with Moderately Severe Psoriasis and the Clinical Significance

目的 对重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(强克)对中重度银屑病患者的临床意义。方法 选取2018年2月至2019年2月在大连市皮肤病医院就诊的100例中重度患有银屑病的患者,按照随机数表法分组,对照组50例采取常规治疗,试验组50例患者在对照组基础上采取重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白进行治疗,两组患者疗程均为12周,比较两组患者临床有效率、随访1年复发情况以及不良反应发生情况。结果 试验组皮损面积和严程度指数(PASI)90%、PASI 75%、PASI50%均优于对照组,差异有统计学意义(P <0.05);试验组结束治疗后3个月、6个月、12个月的复发率低于对照组患者,差异有统计学意义(P <0.05);试验组血小板减、关节酸痛、上呼吸道感染、氨酸氨基转移酶升高情况低于对照组,差异有统计学意义(P <0.05)。结论 采取重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗中重度银屑病患者可以有效提高患者的临床有效率,降低复发率,减少不良反应的发生。

Objective To restructure Ⅱ type of tumor necrosis factor receptor-antibody fusion protein(g) of moderately severe psoriatic patients and the linical significance of pharmacological research.Methods A total of 100 patients with moderate to severe psoriasis who visited Dalian Dermatology Hospital from February 2018 to February 2019 were selected and grouped according to the random number method,on the basis of taking human recombinant Ⅱ type of tumor necrosis factor receptor,antibody fusion protein treatment,two groups of patients with treatment for 12 weeks,compared two groups of patients with clinical efficient,relapse cases were followed up for 1 year and adverse reactions occur.Results The experimental group,PASI 75% PASI 90%,PASI 50% were superior to control group,the difference was statistically significant(P<0.05);the treatment group after treatment for 3 months,6 months,12 months of patients with recurrence rate was lower than the control group,the difference was statistically significant(P<0.05);platelet reduction group,joint pain,upper respiratory tract infection,amino acid increased transaminase is lower than the control group,the difference was statistically significant(P<0.05).Conclusion Patients with moderately severe psoriasis,take human recombinant Ⅱ type of tumor necrosis factor receptor antibody fusion protein,can effectively improve the patient's clinical effectiveness,reduce the recurrence rate,reduce adverse reactions.